Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 9/6/2025

Menopause Treatment Guidelines

Introduction to Menopause Treatment

  • The American College of Obstetricians and Gynecologists recommends menopausal hormone therapy (MHT) as the most effective treatment for managing vasomotor symptoms of menopause, but it should be prescribed at the lowest effective dose for the shortest duration possible due to associated risks 1

Vasomotor Symptoms (Hot Flashes)

  • Estrogen therapy is the most effective treatment for hot flashes, with combination estrogen and progestin for women with an intact uterus, and estrogen alone for women without a uterus 2, 1
  • MHT should be used primarily for symptom management rather than prevention of chronic conditions 1, 3
  • Transdermal routes of administration are preferred as they have less impact on coagulation factors 1
  • SNRIs (e.g., venlafaxine) can reduce hot flash intensity by 40-65% and are considered safe alternatives 1

Genitourinary Symptoms

  • Low-dose vaginal estrogen preparations improve genitourinary symptom severity by 60-80% with minimal systemic absorption 1
  • Vaginal moisturizers can reduce symptom severity by up to 50% as non-hormonal alternatives 1

Risk-Benefit Assessment of Hormone Therapy

  • Reduction in osteoporosis and fractures by approximately 30-50% 1
  • Estrogen and progestin therapy decreases the rates of hip, vertebral, and total fractures 4
  • Estrogen-only therapy is associated with a small reduction in invasive breast cancer risk 5, 6
  • Increased risk of stroke, DVT, gallbladder disease, and urinary incontinence with both estrogen-only and combined therapy 5, 3

Contraindications to Hormone Therapy

  • History of hormone-dependent cancers 2, 7
  • History of abnormal vaginal bleeding 2, 7
  • Active liver disease 2, 7
  • Recent history of pregnancy 2, 7
  • History of thromboembolic events 3

Special Considerations

  • For women with a uterus, combined estrogen and progestin therapy is necessary to prevent endometrial cancer 1
  • For cancer survivors, non-hormonal approaches are generally preferred, especially with hormone-dependent cancers 2, 1
  • The FDA recommends that hormone therapy be prescribed at the lowest effective dose for the shortest duration consistent with treatment goals 8